All Blogs

Jul 15, 2025

Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis p...

Jul 14, 2025

Following an unexpected regulatory delay last month, KalVista Pharmaceuticals has officially entered the commercial market with the FDA approval of its plasma kallikrein inhibitor, sebetralstat. On July 7, 2025, the FDA cleared sebetralstat, now branded as EKTERLY, as an oral treatment for acute hereditary angioede...

Jul 11, 2025

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a serious, progressive complication characterized by increased Pulmonary Vascular Resistance (PVR) and disrupted gas exchange. This rise in PVR places extra stress on the right side of the heart, eventually leading to right heart dysfuncti...

Jul 10, 2025

Intuitive’s da Vinci 5 Surgical System Received CE Mark  On July 02, 2025, Intuitive, widely recognized as a pioneer in robotic-assisted surgery and minimally invasive care, announced that its latest system, the da Vinci 5, had secured CE mark approval for use in both adult and pediatric patients across Eur...

Jul 09, 2025

Menstrual cups, often referred to as a cup for menstruation, have emerged as a transformative option in feminine hygiene, gaining traction in the menstrual cups market worldwide. But what is a menstruation cup? It’s a reusable, bell-shaped device, typically made from silicone cups for menstruation, crafted from med...

Jul 09, 2025

The SUNRISE trial underscores eptinezumab’s preventive efficacy and consistent tolerability profile in a largely Asian chronic migraine population, filling a critical data gap in global neurology care. Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the f...

Jul 09, 2025

ALMB-0166, a novel monoclonal antibody targeting connexin-43 hemichannels, demonstrates favorable safety and neurological recovery signals in acute SCI patients. Early-phase data support continued clinical development of ALMB-0166 as a potential neuroprotective and regenerative therapy following traumatic spina...

Jul 09, 2025

Adjunctive efgartigimod with intravenous methylprednisolone (IVMP) led to greater EDSS improvement and rapid IgG reduction in patients with acute NMOSD and MOGAD. Intensive dosing (20 mg/kg × 2) produced faster neurological recovery and greater antibody titer reductions. At EAN 2025, new data highlighted th...

Jul 09, 2025

Empasiprubart significantly delayed IVIg retreatment and improved grip strength and patient-reported outcomes in both MMN cohorts. Biomarker shifts, including reduced serum NfL levels, indicate axonal preservation and reinforce the neuroprotective potential of C2 inhibition. At European Academy of Neurology...

Jul 09, 2025

Riliprubart demonstrated meaningful clinical benefit across all enrolled cohorts—SoC-Treated, SoC-refractory, and SoC-naïve—with improvement in functional measures (INCAT, I-RODS, MRC-SS, grip strength). Encouraged by consistent Phase II results, two global Phase III trials in CIDP have now been launched, posit...